A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction
NCT ID: NCT00571922
Last Updated: 2017-03-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
72 participants
INTERVENTIONAL
2007-07-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence
NCT00630682
Methylphenidate to Treat Methamphetamine Dependence
NCT01044238
Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
NCT00469508
Modafinil for Methamphetamine Dependence
NCT00859573
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
NCT06721494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acamprosate
Acamprosate
2 gr/day (333 mg, TID)
Placebo
placebo
matching placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acamprosate
2 gr/day (333 mg, TID)
placebo
matching placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment seeking
* Urine sample (+) for methamphetamine
Exclusion Criteria
* Dependence on other drugs (except nicotine)
* DSM-IV axis I disorder unrelated to drug abuse
* Serious medical condition in clinicians opinion.
* AIDs
* Untreated syphilis
* Allergy to acamprosate
* Methadone, or other ORP, maintenance
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malcolm Reid, PhD
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA New York Harbor Healthcare System, MHAD clinic
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-632
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.